First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. (Q39388286)

11 September 2017

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

0 references

Enriqueta Felip

7

0 references

George R Blumenschein

20

object named as

George R Blumenschein

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

19

Hossein Borghaei

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

author name string

David P Carbone

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Martin Reck

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Luis Paz-Ares

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Benjamin Creelan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Leora Horn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Martin Steins

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Michel M van den Heuvel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Tudor-Eliade Ciuleanu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Firas Badin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Neal Ready

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

T Jeroen N Hiltermann

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Suresh Nair

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Rosalyn Juergens

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Solange Peters

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Elisa Minenza

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

John M Wrangle

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Delvys Rodriguez-Abreu

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Liza C Villaruz

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Libor Havel

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Jana Krejci

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Jesus Corral Jaime

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Han Chang

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

William J Geese

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Prabhu Bhagavatheeswaran

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Allen C Chen

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Mark A Socinski

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

CheckMate 026 Investigators

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

Enriqueta Felip

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

language of work or name

English

0 references

publication date

1 June 2017

1 reference

The New England Journal of Medicine

11 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

volume

376

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

issue

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

page(s)

2415-2426

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594.

14 May 2020

cites work

1 reference

12 December 2020

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

12 December 2020

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

12 December 2020

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

1 reference

12 December 2020

PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage

1 reference

12 December 2020

PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-s

1 reference

12 December 2020

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

1 reference

12 December 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

1 reference

12 December 2020

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

12 December 2020

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

1 reference

12 December 2020

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1613493

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6487310&resulttype=core&format=json

14 May 2020

1 reference